Respire_final-01
  • CORPORATE
    • Company Overview
    • Company Management
    • Board of Directors
    • Patents
    • Financial Summary
    • Social Media Guidelines
  • BREATHING DISORDERS
    • Brain-controlled Breathing Disorders
    • Respiratory Depression
    • Sleep Apnea
    • Other Breathing Disorders
    • Additional Reading
  • DEVELOPMENT PROGRAMS
    • Ampakines Platform – As of July 2017
    • Cannabinoids Platform – As of August 2018
  • PRODUCT PIPELINE
  • INVESTORS
    • Investor Contact
    • SEC Reports
    • News
    • FAQs
    • Presentations
    • Financial Summary
  • CONTACT

RespireRx Pharmaceuticals Inc. (formerly Cortex Pharmaceuticals, Inc.) is a biopharmaceutical company focused on the discovery and development of novel drug therapies for the treatment of sleep apnea, drug-induced respiratory depression and other brain-mediated breathing disorders.

In the News

9/9/2019 – RespireRx Pharmaceuticals Inc. Executives Participating in the 2nd Annual International Cannabinoid Derived Pharmaceuticals Summit

September 10, 2019j3ff1

7/30/2019 – RespireRx Pharmaceuticals Inc. Send Notice Letter to the Board of Directors of Therapix Biosciences Ltd.

July 30, 2019j3ff1

2/19/2019 – RespireRx Pharmaceuticals Inc. and Impression Healthcare Limited Announce Agreement to Explore Commercialization of Dronabinol for the Treatment of Obstructive Sleep Apnea in Australia, New Zealand and Southeast Asia

February 19, 2019j3ff1
All News
feature1

Brain-Controlled Breathing Disorders

Breathing is a vital function that is controlled by the rhythmic firing of neurons in a few specific brain regions deep in…

Read More
feature3

Sleep Apnea

According to the National Heart Lung and Blood Institute sleep apnea affects some 18 million Americans. In fact, according to the National Sleep Foundation, about…

Read More
©2016 RespireRx Phamaceuticals Inc. All Rights Reserved.